Lyme disease control 2.0: Advances and opportunities coming with Lyme disease vaccine VLA15

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F25%3A00644009" target="_blank" >RIV/60077344:_____/25:00644009 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1371/journal.ppat.1013747" target="_blank" >https://doi.org/10.1371/journal.ppat.1013747</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.ppat.1013747" target="_blank" >10.1371/journal.ppat.1013747</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lyme disease control 2.0: Advances and opportunities coming with Lyme disease vaccine VLA15

Popis výsledku v původním jazyce

Lyme disease (LD) remains the most prevalent vector-borne disease in the Northern Hemisphere, with over 100,000 cases reported annually in Europe, and ~476,000 in the United States. Although LD can be treated with antibiotics, if detected early, there is currently no licensed vaccine available for humans to prevent infection. One of the key challenges in developing an effective vaccine against LD stems from the complex biology of Borrelia outer surface proteins (Osps), whose expression is dynamically regulated in response to distinct environmental cues, in both the arthropod vector and vertebrate host (Fig 1). Among the predominant outer surface proteins, OspC expression is induced in ticks during Borrelia transmission, and is sustained during early mammalian host infection, while the expression of OspA is restricted only to the tick phase and is no longer expressed in Borrelia once the infection is established in the mammalian host. As a result, infected humans only rarely develop anti-OspA antibodies. Yet, OspA has proven to be a highly effective vaccine antigen, as it induces antibodies that bind to Borrelia within attached ticks, preventing their transmission.

Název v anglickém jazyce

Lyme disease control 2.0: Advances and opportunities coming with Lyme disease vaccine VLA15

Popis výsledku anglicky

Lyme disease (LD) remains the most prevalent vector-borne disease in the Northern Hemisphere, with over 100,000 cases reported annually in Europe, and ~476,000 in the United States. Although LD can be treated with antibiotics, if detected early, there is currently no licensed vaccine available for humans to prevent infection. One of the key challenges in developing an effective vaccine against LD stems from the complex biology of Borrelia outer surface proteins (Osps), whose expression is dynamically regulated in response to distinct environmental cues, in both the arthropod vector and vertebrate host (Fig 1). Among the predominant outer surface proteins, OspC expression is induced in ticks during Borrelia transmission, and is sustained during early mammalian host infection, while the expression of OspA is restricted only to the tick phase and is no longer expressed in Borrelia once the infection is established in the mammalian host. As a result, infected humans only rarely develop anti-OspA antibodies. Yet, OspA has proven to be a highly effective vaccine antigen, as it induces antibodies that bind to Borrelia within attached ticks, preventing their transmission.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PLoS Pathogens

ISSN

1553-7366

e-ISSN

1553-7374

Svazek periodika

21

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

e1013747

Kód UT WoS článku

001639768900001

EID výsledku v databázi Scopus

2-s2.0-105024777430